Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James R Lambert

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Cancer Research|October 3, 2003
Aberrant HOXC expression accompanies the malignant phenotype in human prostateGary J Miller, Heidi L Miller, Adrie van Bokhoven, et al.
Journal of Cellular Physiology|June 3, 2006
Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growthJames R Lambert, Julie A Kelly, Minsub Shim, et al.
Journal of Molecular Biology|June 16, 2012
Glucocorticoid receptor-DNA interactions: binding energetics are the primary determinant of sequence-specific transcriptional activityDavid L Bain, Qin Yang, Keith D Connaghan, et al.
Nucleic Acids Research|September 26, 2013
Steroid receptor-DNA interactions: toward a quantitative connection between energetics and transcriptional regulationDavid L Bain, Keith D Connaghan, Nasib K Maluf, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 15, 2010
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growthJames R Lambert, Vikram J Eddy, Christian D Young, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and AzacitidineChiara R Dart, Nabanita Mukherjee, Carol M Amato, et al.
The Prostate|October 21, 2014
Reduced expression of GDF-15 is associated with atrophic inflammatory lesions of the prostateJames R Lambert, Ramon J Whitson, Kenneth A Iczkowski, et al.
Oncotarget|February 25, 2016
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancersHamid H Gari, Christy M Gearheart, Susan Fosmire, et al.
The Journal of Investigative Dermatology|December 23, 2021
Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 MimeticsNabanita Mukherjee, Chiara R Dart, Carol M Amato, et al.
Molecular Cancer Research : MCR|September 15, 2018
Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of ImmunosuppressionThomas J Rogers, Jessica L Christenson, Lisa I Greene, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer Research|October 3, 2003
Aberrant HOXC expression accompanies the malignant phenotype in human prostateGary J Miller, Heidi L Miller, Adrie van Bokhoven, et al.
Journal of Cellular Physiology|June 3, 2006
Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growthJames R Lambert, Julie A Kelly, Minsub Shim, et al.
Journal of Molecular Biology|June 16, 2012
Glucocorticoid receptor-DNA interactions: binding energetics are the primary determinant of sequence-specific transcriptional activityDavid L Bain, Qin Yang, Keith D Connaghan, et al.
Nucleic Acids Research|September 26, 2013
Steroid receptor-DNA interactions: toward a quantitative connection between energetics and transcriptional regulationDavid L Bain, Keith D Connaghan, Nasib K Maluf, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 15, 2010
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growthJames R Lambert, Vikram J Eddy, Christian D Young, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and AzacitidineChiara R Dart, Nabanita Mukherjee, Carol M Amato, et al.
The Prostate|October 21, 2014
Reduced expression of GDF-15 is associated with atrophic inflammatory lesions of the prostateJames R Lambert, Ramon J Whitson, Kenneth A Iczkowski, et al.
Oncotarget|February 25, 2016
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancersHamid H Gari, Christy M Gearheart, Susan Fosmire, et al.
The Journal of Investigative Dermatology|December 23, 2021
Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 MimeticsNabanita Mukherjee, Chiara R Dart, Carol M Amato, et al.
Molecular Cancer Research : MCR|September 15, 2018
Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of ImmunosuppressionThomas J Rogers, Jessica L Christenson, Lisa I Greene, et al.
Pageof 4